Results 31 to 40 of about 10,696 (166)

Elevated l-threonine is a biomarker for Lassa fever and Ebola

Virology Journal, 2020
Background Lassa fever and Ebola are characterized by non-specific initial presentations that can progress to severe multisystem illnesses with high fatality rates.
Trevor V. Gale, John S. Schieffelin, Luis M. Branco, Robert F. Garry, Donald S. Grant   +4 more
doaj   +1 more source

Ebola Virus Hemorrhagic Fever [PDF]

Microscopy and Microanalysis, 2015
This past year has seen the largest Ebola virus outbreak on record, centered in West Africa in Guinea, Liberia, and Sierra Leone. 1 Cases were first reported in Guinea on March 21, 2014; by March 30, cases were reported in Liberia and in May Sierra Leone also reported cases.
openaire   +1 more source

Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time

Nature Communications, 2020
Outbreaks of viral hemorrhagic fevers highlight the need for sensitive, field-deployable diagnostics. Here the authors present a CRISPR-based SHERLOCK platform with field protocol and mobile app for Ebola and Lassa fever outbreaks.
Kayla G. Barnes, Anna E. Lachenauer, Adam Nitido, Sameed Siddiqui, Robin Gross, Brett Beitzel, Katherine J. Siddle, Catherine A. Freije, Bonnie Dighero-Kemp, Samar B. Mehta, Amber Carter, Jessica Uwanibe, Fehintola Ajogbasile, Testimony Olumade, Ikponmwosa Odia, John Demby Sandi, Mambu Momoh, Hayden C. Metsky, Chloe K. Boehm, Aaron E. Lin, Molly Kemball, Daniel J. Park, Luis Branco, Matt Boisen, Brian Sullivan, Mihret F. Amare, Abdulwasiu B. Tiamiyu, Zahra F. Parker, Michael Iroezindu, Donald S. Grant, Kayvon Modjarrad, Cameron Myhrvold, Robert F. Garry, Gustavo Palacios, Lisa E. Hensley, Stephen F. Schaffner, Christian T. Happi, Andres Colubri, Pardis C. Sabeti   +38 more
doaj   +1 more source

Differences in cynomolgus macaque populations used for infectious disease research. [PDF]

Animal Model Exp Med
Cynomolgus macaques, a species of Old World primate native to southeastern and eastern Asia and the island of Mauritius, are one of the most important nonhuman primate models for infectious disease. Research into the population genetics of cynomolgus macaques has found significant differences between macaques native to different areas, particularly ...
Quist D, Ebisine K, Kennedy E, Dowall S, Dennis M.   +4 more
europepmc   +2 more sources

Ebola Hemorrhagic Fever and Septic Shock [PDF]

The Journal of Infectious Diseases, 2003
Ebola virus is the cause of sporadic outbreaks of lethal Ebola hemorrhagic fever (EHF) in central Africa. Despite the difficulties of studying this virus much has been learned over the past decade about the pathogenesis of Ebola virus infection in humans and nonhuman primates.
Mike Bray, Siddhartha Mahanty
openaire   +1 more source

Marburg and Ebola Hemorrhagic Fevers (Filoviruses)

, 2015
Thomas W Geisbert
exaly   +2 more sources

Secreted Nonstructural Protein 3 is a Pathogenic Determinant of Orbivirus

Advanced Science, EarlyView.
This study uncovers a conserved PIP2‐dependent secretory pathway of orbivirus NS3 that induces vascular leakage. Pharmacological disruption of PIP2‐NS3 interaction significantly reduces viral pathogenicity and provides protective efficacy in murine models, establishing PIP2‐mediated NS3 secretion as both a key virulence determinant and a promising ...
Junyong Guan, Dong Zhou, Ran Shao, Xing Liu, Jin Peng, Yingran Huang, Shuhui Qi, Cankun Xi, Menghang Wang, Bin Sun, Yinglin Qi, Xin Yin   +11 more
wiley   +1 more source

Undiagnosed Acute Viral Febrile Illnesses, Sierra Leone

Emerging Infectious Diseases, 2014
Sierra Leone in West Africa is in a Lassa fever–hyperendemic region that also includes Guinea and Liberia. Each year, suspected Lassa fever cases result in submission of ≈500–700 samples to the Kenema Government Hospital Lassa Diagnostic Laboratory in ...
Randal J. Schoepp, Cynthia A. Rossi, Sheik H. Khan, Augustine Goba, Joseph N. Fair   +4 more
doaj   +1 more source

Evaluation of the Effectiveness of Nonspecific Medical Protection Against Diseased, Caused of Ebola Virus

Антибиотики и Химиотерапия, 2020
The article presents an analysis of research evaluating the effectiveness of nonspecific means of emergency prevention and treatment of Ebola virus disease.
T. E. Sizikova, v. N. Lebedev, A. A. Petrov, S. V. Borisevich   +3 more
doaj   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source